7Baggers

Anavex Life Sciences Corp
(NASDAQ:AVXL) 

AVXL stock logo

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Pha...

Founded: 2004
Full Time Employees: 16
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 2017-06-30 2017-03-31 2016-12-31 2016-09-30 2016-06-30 2016-03-31 2015-12-31 2015-09-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-03-31 2013-09-30 2013-06-30 2013-03-31 2012-12-31 2012-09-30 2012-06-30 2012-03-31 2011-12-31 2011-09-30 2011-06-30 2011-03-31 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2009-12-31 2009-09-30 2008-12-31 2008-09-30 
                                                                      
      operating expenses
    		                                                                  
      general and administrative
    		2,126,000 3,550,000 4,500,000 2,621,000 3,146,000 2,781,000 2,859,000 2,790,000 2,609,000 2,591,553 3,247,843 2,882,568 3,317,036 3,902,508 3,185,451 2,915,158 3,066,951 2,878,983 2,434,127 2,233,745 1,470,656 1,402,955 1,381,477 1,720,142 1,352,035 1,635,312 1,388,729 2,061,251 1,761,307 1,481,538 1,620,379 1,489,450 1,397,803 1,361,051 1,405,026 1,116,014 1,126,184 2,243,905 1,376,362 852,775 3,861,698                          
      research and development
    		4,656,000 7,294,000 9,959,000 9,892,000 10,446,000 11,555,000 11,870,000 9,729,000 8,684,000 10,060,636 10,282,854 11,306,591 12,066,919 11,381,450 9,273,269 8,604,589 8,656,439 9,372,786 8,964,528 6,720,841 7,925,519 6,104,906 6,725,002 6,053,047 6,348,668 4,710,907 5,758,446 6,078,786 5,712,210 4,407,452 2,997,634 3,245,023 2,694,312 3,836,386 2,300,277 2,492,933 2,042,490 4,338,871 917,303 1,327,393 670,736  407,146 318,625 344,048 265,015 118,152   560 12,685,952 635,225.75 393,963 429,607 1,717,333 7,899,586 777,971 8,535,342 7,805,100 5,667,561 613,161 815,609 211,479  284,104  
      total operating expenses
    		6,782,000 10,844,000 14,459,000 12,513,000 13,592,000 14,336,000 14,729,000 12,519,000 11,293,000 12,652,189 13,530,697 14,189,159 15,383,955 86,687,672 -12,458,720 -11,519,747 -11,723,390 -12,251,769 -11,398,655 -8,954,586 -9,396,175 -7,507,861 -8,106,479 -7,773,189 -7,700,703 -6,346,219 -7,147,175 -8,140,037 -7,473,517 -5,888,990 -4,618,013 -4,734,473 -4,092,115 -5,197,437 -3,705,303 -3,608,947 -3,168,674 -6,582,776 -2,293,665 -2,180,168 -4,532,434                          
      operating income
    		-6,782,000 -10,844,000 -14,459,000 -12,513,000 -13,592,000 -14,336,000 -14,729,000 -12,519,000 -11,293,000 -12,652,189 -13,530,697 -14,189,159 -15,383,955                                                      
      yoy
    		-50.10% -24.36% -1.83% -0.05% 20.36% 13.31% 8.86% -11.77% -26.59%                                                          
      qoq
    		-37.46% -25.00% 15.55% -7.94% -5.19% -2.67% 17.65% 10.86% -10.74% -6.49% -4.64% -7.77%                                                       
      other income
    		                                                                  
      grant income
    		  25,000  12,000        25,000      43,280 10,820    74,944 74,944 74,944 74,944 74,527 74,528 74,527 74,528   19,826 69,146 16,684 35,286 27,494 47,767 26,879 610,148                          
      research and development incentive income
    		33,000 13,000 127,000 96,000 412,000 700,000 526,000 472,000 592,000 669,887 564,842 749,681 733,590 994,336 682,432 835,513 810,730 953,243 1,363,661 960,879 1,269,316 1,394,569 1,319,913 717,328 943,215      1,629,513     2,022,902                               
      interest income
    		1,079,000 999,000 1,075,000 1,210,000 1,394,000 1,759,000 1,796,000 1,756,000 2,008,000 1,958,216 1,827,945 1,465,221 1,267,618 704,583 229,917 7,578 4,910 7,151 11,453 9,216  6,977 56,096 70,180 46,720 42,177 34,838 51,465 78,800 83,843 112,226 28,647 30,376 12,119.75 26,677 18,147 3,655 4,490 2,626 2,064                           
      foreign exchange gain
    		7,000 5,000 -11,000 11,000 -337,000 117,000 67,000 -150,000 156,000 36,559.75 -101,066 -118,678 365,983   268,645 55,363 -284,535 -160,880 -154,563 332,634 149,722 248,665 -325,960 53,113 -37,535 -54,546 54,199  -5,708.25 -16,475 -18,337 11,979 -7,455 -65,932 11,722 14,082 -10,808 8,924 -30,906 -15,655  43,609 23,318   8,397   37,569  11,260.5 37,904  39,556     -74,892 44,268 26,042 8,270  9,172  
      total other income
    		1,119,000 1,017,000 1,216,000 1,317,000 1,481,000 2,592,000 2,448,000 2,078,000 2,756,000 2,442,208 2,291,721 1,131,880 2,392,191 1,203,849 179,800 1,111,736 871,003 675,859 1,257,514 826,352 1,600,391 1,551,268 1,624,674 536,492 1,117,992 2,472,924 92,214 180,191 148,821 131,414 1,768,849 10,310 42,355 51,990 105,095 2,069,455 53,023                              
      net loss before provision for income taxes
    		-5,663,000     -11,744,000 -12,281,000 -10,441,000 -8,537,000 -10,209,981 -11,238,976 -13,057,279 -12,991,764 -14,080,109 -12,278,920 -10,408,011 -10,852,387 -11,575,910 -10,141,141 -8,128,234 -7,795,784 -5,956,593 -6,481,805 -7,236,697 -6,582,711 -3,873,295 -7,054,961 -7,959,846 -7,324,696 -5,757,576 -2,849,164 -4,724,163 -4,049,760 -5,145,447 -3,600,208 -1,539,492 -3,115,651 -6,505,032 -2,234,356 -2,030,801 -3,936,894                          
      income tax expense, current
    		-18,000       -105,000  63,954 -41,000 -50,000  -210,291 -88,421 -29,800 -29,980 -142,296 -39,000 -26,988 -59,281 -8,633 -4,817  -9,214                                          
      net loss and comprehensive loss
    		-5,681,000 -9,827,000 -13,243,000 -11,196,000 -12,111,000 -11,620,000 -12,214,000 -10,546,000 -8,622,000 -10,146,027 -11,279,976 -13,107,279 -12,971,718 -14,290,400 -12,367,341 -10,437,811 -10,882,367 -11,718,206 -10,180,141 -8,155,222 -7,855,065 -5,965,226 -6,486,622 -7,236,697 -6,591,925 -3,879,411 -7,074,261 -8,007,894 -7,333,413 -5,793,056 -2,849,164 -4,752,024 -4,059,165 -5,154,574 -3,610,085 -1,549,087 -3,146,659                              
      net income per share
    		                                                                  
      basic and diluted
    		-0.06 -0.11 -0.16 -0.13 -0.14 -0.14 -0.14 -0.13 -0.11 -0.118 -0.14 -0.17 -0.17 -0.18 -0.16 -0.14 -0.14 -0.15 -0.14 -0.12 -0.12 -0.1 -0.11 -0.12 -0.12                                          
      weighted-average number of shares outstanding
    		                                                 30,240,687   28,355,453 27,342,977 26,738,857  25,294,101      21,007,630  19,965,300  
      basic and diluted
    		89,029,458 85,289,447 85,380,587 85,073,769 84,805,974 83,468,049 84,535,328 82,464,226    78,304,363 77,977,112 76,909,993 77,442,236 76,248,603 75,997,738 69,802,960 70,589,561 68,594,867 64,295,143 58,194,894 59,105,399 58,353,954 54,773,685 48,906,470 49,622,465 47,134,686 46,327,482  45,212,074 44,545,523 43,882,939 40,841,033 41,509,225                                
      other financing expense
    		         344  -964,344                                                       
      gain on settlement of accounts payable
    		     14,750 59,000                   78,780 36,978        75,204     151,402     194,155 5,500                     
      income tax recovery (expense), current
    		     -31,000 67,000  -85,000    20,046                                                      
      weighted average number of shares outstanding
    		                                                                  
      basic and diluted
    		        82,077,815  80,875,235                                                        
      foreign exchangegain
    		             -102,135.25 -732,549                                                    
      interest (expense) income
    		                    -1,559                                              
      financing related charges
    		                              -30,943                                    
      income tax expense
    		                         -19,016.25 -19,300 -48,048 8,717 110,012  -27,861 9,405     -5,903.75 -6,000  17,615                          
      loss per share
    		                                                                  
      basic and diluted
    		                         -0.118 -0.14 -0.17 -0.16 -0.065 -0.06 -0.11 -0.09 -0.12 -0.09                                
      foreign exchange gain or loss net
    		                            -4,507                                      
      financing related charges and adjustments
    		                                     -4,637 -8 -72 -1,095   37,651                       
      income tax expense - current
    		                                 -12,620 -9,877 -9,595 -31,008                              
      loss per share
    		                                                                  
      basic
    		                                   -0.04 -0.08 -0.18 -0.06 -0.06 -0.12                          
      diluted
    		                                   -0.04 -0.08 -0.18 -0.06 -0.06 -0.12                          
      weighted-average number of shares outstanding
    		                                                 30,240,687   28,355,453 27,342,977 26,738,857  25,294,101      21,007,630  19,965,300  
      basic
    		                                   41,159,707 38,393,910 35,153,426 35,709,686 35,214,793 33,971,913 18,584,820 57,307,779 51,630,390 39,727,731 39,260,098 37,881,209                    
      diluted
    		                                   41,159,707 38,393,910 35,153,426 35,709,686 35,214,793 33,971,913 18,584,820 57,307,779 51,630,390 39,727,731 39,260,098 37,881,209                    
      total other income (expenses)
    		                                     77,744 59,309 149,367 595,540    165,073.75  2,307                    
      net loss and comprehensive loss for the period
    		                                     -2,056,416.5 -2,240,356 -2,030,801 -3,954,509                          
      interest and finance expenses
    		                                        2,142                          
      general and administrative - notes 8 and 9
    		                                          451,193 452,053                       
      interest and finance income (expenses)
    		                                          2,228                        
      general and administrative - notes 9 and 10
    		                                            485,315.25 733,818 903,015                    
      accretion of debt discounts
    		                                                                  
      change in fair value of derivative financial instruments
    		                                            170,750                      
      foreign exchange loss
    		                                                                  
      debt conversion expense
    		                                                                  
      loss on settlement of accounts payable
    		                                                                  
      loss on extinguishment of debt
    		                                                                  
      expenses
    		                                                                  
      accounting and audit fees
    		                                               693,596 767,390 15,908 729,114 543,150 24,436 23,784 70,744 395,805 39,220 451,456 413,076 248,350 26,983 66,936 21,859  31,260  
      amortization and depreciation
    		                                               5,055 5,631 111 5,520 3,661 465 465 464 1,922 377 2,438 2,031        
      bank charges and interest
    		                                               44,796 44,215 709 42,797 37,469 1,568 947 2,323 29,826 2,727 31,434 29,686 23,226 1,427 1,275 1,715  876  
      consulting fees - note 6 and 7
    		                                               59,724.5 11,982,989 74,401 11,879,502                
      insurance
    		                                                58,996  58,996 49,366   12,783 10,293 16,937 20,922 4,815        
      investor relations
    		                                               928,803 863,186 15,000 850,307 794,069 15,000 7,638 15,000 605,382 38,652 669,299 644,299 478,037 29,734 27,482 54,511  25,000  
      legal fees
    		                                               746,569 769,799 14,354 727,569 572,242 21,629 48,143 28,011 410,392 59,363 443,836 406,236 285,980 54,826 17,775 27,908  3,610  
      management fees - note 6
    		                                                14,625  14,625                
      office and miscellaneous expense
    		                                               151,296 148,091 112                 
      registration and filing fees
    		                                               169,534 172,896 5,769 163,752 133,639 3,110 9,237 8,412 72,799 9,380 114,151 77,788 51,606 7,667 3,320 6,133  5,576  
      rent and administration
    		                                                224,670  224,670     169,498 2,354 214,378 203,379        
      research and development - note 7
    		                                               41,646 12,725,533                  
      travel
    		                                               755,290 746,715 187 741,155 682,328 4,464 31,200 23,163 562,703 59,864 543,810 523,784        
      website design and maintenance
    		                                                28,417  28,417       28,417 28,417 26,725 1,692      
      income before other income
    		                                                                  
      interest and financing fees
    		                                                                  
      accretion of debt discount
    		                                                                  
      change in fair value of derivative liability
    		                                                                  
      net income for the period
    		                                                                  
      basic and diluted loss per share
    		                                                                  
      weighted-average number of shares outstanding
    		                                                 30,240,687   28,355,453 27,342,977 26,738,857  25,294,101      21,007,630  19,965,300  
      current
    		                                                                  
      cash
    		                                                 487    178,647      364,609.75 1,458,439 144,510 21,034  614  
      deferred financing charge
    		                                                                  
      equipment - note 3
    		                                                     1,505             
      liabilities
    		                                                                  
      accounts payable and accrued liabilities - note 6
    		                                                 2,673,983                 
      promissory notes payable - note 4
    		                                                 761,292                 
      capital deficit
    		                                                                  
      capital stock - note 5
    		                                                                  
      authorized: 150,000,000 common shares, par value 0.001 per share issued and outstanding: 30,240,687 common shares
    		                                                 30,241                 
      additional paid-in capital
    		                                                 34,599,514    29,329,105      2,952,013.25 11,808,053 9,191,534 8,762,948  4,891,179  
      deficit accumulated during the development stage
    		                                                                  
      basis of presentation and liquidity - note 1
    		                                                                  
      loss before other income
    		                                                                  
      net loss for the period
    		                                                                  
      office and miscellaneous
    		                                                  147,684 139,264 2,965 2,283 3,172 113,922 4,995 128,089 114,938 -76,931 83,269 17,403 84,728  40,640  
      consulting fees - note 7 and 8
    		                                                   10,964,264 230,313 242,302 307,212            
      management fees
    		                                                         14,625 14,625        
      accretion of debt discount - note 5
    		                                                                  
      change in fair value of derivative liability - note 4
    		                                                   16,875  12,500 55,000            
      loss on extinguishment of debt - notes 5 and 6
    		                                                                  
      vat recoverable
    		                                                     953             
      deferred financing charge - note 5
    		                                                     9,995             
      prepaid expenses
    		                                                           10,407.5 41,630 168     
      accounts payable and accrued liabilities - note 7
    		                                                     1,918,747             
      derivative liability - note 4
    		                                                                  
      promissory notes payable - note 5
    		                                                     1,200,707             
      capital stock - note 6
    		                                                                  
      authorized: 150,000,000 common shares, par value 0.001 per share issued and outstanding: 27,465,174 common shares
    		                                                     27,466             
      consulting fees - note 6
    		                                                       573,800.25 625,298          
      interest
    		                                                                  
      accretion of debt discount - note 4
    		                                                                  
      change in fair value of derivative liability - note 3
    		                                                       27,500 110,000          
      debt conversion expense - note 4
    		                                                                  
      loss on settlement of accounts payable - note 5
    		                                                                  
      loss on extinguishment of debt - note 4
    		                                                                  
      consulting fees – note 5
    		                                                         9,500,793 8,483,091        
      debt conversion expense – note 3
    		                                                                  
      loss on extinguishment of debt – note 3
    		                                                                  
      debt conversion expense - note 3
    		                                                                  
      deferred financing charges – note 5
    		                                                           9,320.75 37,283      
      equipment
    		                                                           280.25 1,121 1,311 1,501  772  
      accounts payable and accrued liabilities – note 7
    		                                                           443,701.5 1,774,806 1,746,061     
      derivative liabilities – note 4
    		                                                           876,744.5 3,506,978      
      promissory note payable – note 5
    		                                                           650,397 2,601,588      
      stockholders’ deficiency
    		                                                                  
      capital stock – note 6
    		                                                                  
      authorized:
    		                                                                  
      150,000,000 common shares, par value 0.001 per share
    		                                                                  
      issued and outstanding:
    		                                                                  
      22,106,256 common shares
    		                                                           5,526.75 22,107      
      share subscriptions received
    		                                                             149,470     
      amortization
    		                                                           142.5 190 190 190  90  
      consulting – note 7
    		                                                           376,701.25 483,915 568,816     
      rent
    		                                                                  
      loss before other items
    		                                                                  
      interest on long-term debt
    		                                                                  
      accretion
    		                                                                  
      change in fair value of derivative
    		                                                                  
      liability – note 4
    		                                                                  
      loss on extinguishment of
    		                                                                  
      promissory notes
    		                                                                  
      weighted-average shares outstanding
    		                                                            21,163,209 21,044,780     
      deferred financing charges
    		                                                             83,108 49,951    
      derivative liabilities – notes 3 and 4
    		                                                             521,332 432,508    
      promissory notes payable – note 5
    		                                                             2,425,059 123,981    
      authorized: 150,000,000 common shares, par value 0.001 per share
    		                                                                  
      issued and outstanding: 21,062,932 common shares
    		                                                             21,063     
      interest on long – term debt
    		                                                                  
      change in fair value of derivative liability – note 4
    		                                                              649,038    
      loss on extinguishment of promissory notes
    		                                                                  
      prepaid expense
    		                                                              178    
      accounts payable and accrued liabilities
    		                                                              1,570,482    
      current portion of promissory notes payable – note 5
    		                                                              2,428,441    
      21,013,427 common shares
    		                                                              21,014    
      consulting fees – notes 7 and 8
    		                                                              454,074    
      management fees – note 7
    		                                                                  
      rent and administration – note 7
    		                                                                  
      loss before other item
    		                                                                  
      loss on extinguishment of promissory note
    		                                                                  
      assets
    		                                                                  
      accounts payable and accrued liabilities – note 5
    		                                                                1,073,951  
      promissory notes payable – note 3
    		                                                                1,684,500  
      capital stock – note 4
    		                                                                  
      19,982,420 common shares
    		                                                                19,982  
      shares to be issued – note 5
    		                                                                194,549  
      share subscriptions received – note 8
    		                                                                128,081  
      consulting fees – notes 5 and 6
    		                                                                515,567  
      management fees – note 5
    		                                                                  
      rent and administration – note 5
    		                                                                  
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 2018-09-30 2018-06-30 2018-03-31 2017-12-31 2017-09-30 
                                        
        assets
      		                                  
        current
      		                                  
        cash and cash equivalents
      		131,749,000 102,577,000 101,164,000 115,771,000 120,775,000 132,187,000 138,756,000 139,386,000 143,765,000 151,024,000 154,817,164 153,466,962 143,621,848 149,157,861 153,199,352 153,342,556 151,146,355 152,107,745 157,560,045 75,859,339 47,357,599 29,249,018 27,619,145 26,563,071 27,458,423 22,185,630 21,249,206 19,457,845 20,715,169 22,930,638 25,827,592 25,656,584 28,048,644 27,440,257 
        incentive and tax receivables
      		844,000 809,000 820,000 666,000 2,557,000 2,449,000 1,720,000 3,785,000 3,549,000 2,709,000 2,165,127 4,737,661 4,094,431 3,192,580 6,559,829 6,468,987 5,372,153 9,136,831 8,601,258 7,328,090 6,577,807 4,849,340 3,547,972 4,151,947 3,730,672 2,642,745         
        prepaid expenses and other current assets
      		396,000 429,000 448,000 702,000 711,000 931,000 1,059,000 1,345,000 756,000 653,000 827,572 981,774 655,643 354,162 461,963 464,605 377,860                  
        total assets
      		132,989,000 103,815,000 102,432,000 117,139,000 124,043,000 135,567,000 141,535,000 144,516,000 148,070,000 154,386,000 157,809,863 159,186,397 148,371,922 152,704,603 160,221,144 160,276,148 156,896,368 161,616,490 166,419,501 83,574,238 54,334,246 34,542,197 31,630,256 31,020,577 31,424,067 25,329,373 21,968,271 20,549,780 22,095,679 24,376,136 26,794,693 25,895,594 28,343,807 27,838,329 
        liabilities and stockholders’ equity
      		                                  
        current liabilities
      		                                  
        accounts payable
      		2,639,000 4,249,000 6,740,000 6,997,000 4,567,000 9,627,000 3,503,000 3,726,000 4,292,000 4,322,000 4,152,846 6,281,742 5,288,261 3,824,777 3,126,892 2,631,888 4,634,791 4,739,781 4,176,707 3,658,052 4,216,948 3,989,054 3,980,204 3,649,734 3,127,498 3,523,332         
        accrued liabilities - note 3
      		2,927,000 3,892,000 3,929,000 9,555,000 7,732,000 4,835,000    7,295,000        5,614,774                 
        deferred grant income - note 4
      		805,000 805,000 805,000 829,000 829,000 842,000    917,000                         
        total liabilities
      		6,371,000 8,946,000 11,474,000 17,381,000 13,128,000 15,304,000 11,754,000 9,558,000 12,495,000 12,534,000 11,055,267 14,021,343 13,247,846 10,213,561 9,484,544 8,071,107 10,528,662 10,798,386 9,273,772 7,763,942 8,033,469 7,305,628 6,949,198 6,228,831 5,463,917 5,039,674 4,336,607 6,370,604 4,875,895 3,884,626 3,209,070 3,416,737 2,798,472 3,584,334 
        commitments and contingencies - note 6
      		                                  
        capital stock
      		                                  
        authorized:
      		                                  
        10,000,000 preferred stock, par value 0.001 per share...
      		                                  
        200,000,000 common stock, par value 0.001 per share...
      		                                  
        issued and outstanding:
      		                                  
        92,671,758 common shares
      		93,000                                  
        additional paid-in capital
      		514,654,000 477,230,000 463,494,000 459,051,000 459,012,000 456,249,000 454,236,000 447,345,000 437,184,000 434,839,000 429,595,961 416,727,598 393,581,544 387,976,881 381,932,039 371,437,616 354,759,781 348,328,048 342,938,236 251,427,781 213,766,108 186,851,752 178,332,979 171,958,462 165,891,753 153,633,807 148,927,688 138,696,975 133,438,276 129,377,542 126,679,219 122,724,029 121,038,635 115,689,221 
        accumulated deficit
      		-388,129,000 -382,448,000 -372,621,000 -359,378,000 -348,182,000 -336,071,000 -324,451,000 -312,237,000 -301,691,000 -293,069,000 -282,922,756 -271,642,780 -258,535,501 -245,563,783 -231,273,383 -218,906,042 -208,468,231 -197,585,864 -185,867,658 -175,687,517 -167,532,295 -159,677,230 -153,712,004 -147,225,382 -139,988,685 -133,396,760 -131,347,535 -124,273,274 -116,265,380 -108,931,967 -103,138,911 -100,289,747 -95,537,723 -91,478,558 
        total stockholders’ equity
      		126,618,000 94,869,000 90,958,000 99,758,000 110,915,000 120,263,000           146,367,706  157,145,729 75,810,296       17,631,664 14,179,176 17,219,784 20,491,510 23,585,623 22,478,857 25,545,335 24,253,995 
        total liabilities and stockholders’ equity
      		132,989,000 103,815,000 102,432,000 117,139,000 124,043,000 135,567,000           156,896,368  166,419,501 83,574,238       21,968,271 20,549,780 22,095,679 24,376,136 26,794,693 25,895,594 28,343,807 27,838,329 
        86,668,521 common shares
      		 87,000                                 
        85,411,692 common shares
      		  85,000                                
        85,333,652 common shares
      		   85,000                               
        84,985,449 common shares
      		    85,000                              
        84,795,517 common shares
      		     85,000 85,000                            
        liabilities and stockholders' equity
      		                                  
        accrued liabilities - note 4
      		      7,334,000 4,915,000 7,286,000  5,985,658 6,822,838 7,042,822                      
        deferred grant income - note 3
      		      917,000 917,000 917,000  916,763 916,763 916,763                      
        share proceeds receivable
      		      -89,000 -234,000        -403,696                   
        total stockholders' equity
      		      129,781,000 134,958,000 135,575,000 141,852,000 146,754,596 145,165,054 135,124,076 142,491,042 150,736,600 152,205,041  150,818,104   46,300,777 27,236,569 24,681,058 24,791,746 25,960,150 20,289,699         
        total liabilities and stockholders' equity
      		      141,535,000 144,516,000 148,070,000 154,386,000 157,809,863 159,186,397 148,371,922 152,704,603 160,221,144 160,276,148  161,616,490   54,334,246 34,542,197 31,630,256 31,020,577 31,424,067 25,329,373         
        83,616,218 common shares
      		       84,000                           
        82,086,511 common shares
      		        82,000                          
        issued and outstanding: 82,066,511 common shares
      		         82,000                         
        81,390,916 common shares
      		          81,391                        
        80,235,398 common shares
      		           80,236                       
        78,032,135 common shares
      		            78,033                      
        accrued liabilities
      		             5,944,953 5,913,821 4,995,388 5,450,040  4,653,234 3,618,779 3,816,521 3,316,574 2,968,994 2,579,097 2,336,419 1,516,342         
        deferred grant income
      		             443,831 443,831 443,831 443,831 443,831 443,831 487,111               
        77,942,815 common shares
      		             77,944                     
        current assets
      		                                  
        stockholders' equity
      		                                  
        77,942,568 common shares
      		                                  
        77,161,688 common shares
      		                                  
        stockholders’ equity
      		                                  
        76,155,187 common shares
      		                                  
        prepaid expenses and deposits
      		                 355,549 258,198 386,809 398,840 443,839 438,631 305,559 234,972 500,998         
        deferred financing charges
      		                 16,365             50,000 30,943   
        75,918,465 common shares
      		                 75,920                 
        commitments and contingencies - note 5
      		                                  
        200,000,000 100,000,000 common stock, par value 0.001 per share...
      		                                  
        75,149,833 common shares
      		                  75,151                
        100,000,000 common stock, par value 0.001 per share...
      		                                  
        70,030,620 common shares
      		                                  
        operating expenses
      		                                  
        general and administrative
      		                   2,233,745       1,388,729 2,061,251 1,761,307 5,989,170 1,620,379 1,489,450 1,397,803 5,008,275 
        research and development
      		                   6,720,841       5,758,446 6,078,786 5,712,210 13,344,421 2,997,634 3,245,023 2,694,312 10,672,086 
        total operating expenses
      		                   -8,954,586       -7,147,175 -8,140,037 -7,473,517 -19,333,591 -4,618,013 -4,734,473 -4,092,115 -15,680,361 
        other income
      		                                  
        grant income
      		                   10,820       74,944 74,527 74,528 149,055 74,528   140,942 
        research and development incentive income
      		                   960,879          1,629,513 1,629,513   2,022,902 
        interest income
      		                   9,216       34,838 51,465 78,800 255,092 112,226 28,647 30,376  
        foreign exchange gain
      		                   -154,563       -54,546 54,199   -16,475 -18,337 11,979 -47,583 
        total other income
      		                   826,352       92,214 180,191 148,821 1,952,928 1,768,849 10,310 42,355 2,279,563 
        net income before benefit from income taxes
      		                   -8,128,234       -7,054,961 -7,959,846 -7,324,696 -17,380,663 -2,849,164 -4,724,163 -4,049,760 -13,400,798 
        income tax expense, current
      		                   -26,988               
        net income and comprehensive loss
      		                   -8,155,222       -7,074,261 -8,007,894 -7,333,413 -17,453,409 -2,849,164 -4,752,024 -4,059,165 -13,460,405 
        net income per share
      		                                  
        basic and diluted
      		                   -0.12       -0.14 -0.17 -0.16  -0.06 -0.11 -0.09 -0.33 
        weighted-average number of shares outstanding
      		                                  
        66,962,957 common shares
      		                    66,964              
        62,045,198 common shares
      		                     62,047             
        deferred costs
      		                      24,508    151,133 151,133 151,133 101,133     
        total current assets
      		                      31,630,256   25,329,373         
        60,082,291 common shares
      		                      60,083            
        58,664,946 common shares
      		                       58,666           
        commitments - note 5
      		                                  
        57,080,356 common shares
      		                        57,082          
        deposits
      		                             52,396 52,396 52,396 52,396 52,396 
        52,650,251 common shares
      		                         52,652         
        sales tax recoverable
      		                          93,314 76,160 30,372 40,171 6,145 5,011 7,377 9,748 
        prepaid expenses
      		                          459,618 849,642 1,155,958 1,251,798 858,560 150,660 235,390 335,928 
        deposits - short term
      		                          15,000 15,000 43,047      
        accounts payable and accrued liabilities
      		                          4,336,607 6,370,604 4,875,895 3,884,626 3,209,070 3,416,737 2,798,472 3,584,334 
        51,509,871 common shares
      		                          51,511        
        gain on settlement of accounts payable
      		                          36,978       75,204 
        financing related charges
      		                             -30,943 -30,943    
        income tax expense
      		                          -19,300 -48,048 8,717 72,746  -27,861 9,405 59,607 
        loss per share
      		                                  
        100,000,000 common shares, par value 0.001 per share...
      		                                  
        48,173,241 common shares
      		                                  
        subscriptions receivable
      		                           -292,700       
        46,887,056 common shares
      		                                  
        foreign exchange gain or loss net
      		                            -4,507      
        liabilities and stockholders’ equity current
      		                                  
        45,933,472 common shares
      		                             45,935     
        gain on settlement of debt
      		                                  
        foreign exchange loss
      		                             -49,789     
        loss per share basic and diluted
      		                             -0.39     
        weighted-average number of shares outstanding basic and diluted
      		                             44,655,725     
        commitments - note 6
      		                                  
        45,314,155 common shares
      		                              45,315    
        44,573,788 common shares
      		                               44,575   
        44,421,992 common shares
      		                                44,423  
        43,330,817 common shares
      		                                 43,332 
        interest income
      		                                 88,098 
        financing related charges and adjustments
      		                                  
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2025-06-30 2025-03-31 2024-12-31 2024-06-30 2024-03-31 2023-12-31 2019-03-31 2015-09-30 2015-03-31 2014-12-31 2014-09-30 2014-06-30 2014-01-23 2013-12-31 2013-09-30 2013-06-30 2013-01-23 2012-12-31 2012-09-30 2012-06-30 2012-01-23 2011-12-31 2011-09-30 2011-06-30 2010-12-31 2010-09-30 2010-06-30 2010-03-31 2010-01-23 2009-12-31 2009-09-30 2009-06-30 2008-12-31 
                                         
          cash flows used in operating activities
        		                                 
          net income
        		-36,550,000 -23,307,000 -12,111,000 -12,214,000 -10,546,000 -8,622,000 -15,341,307                           
          adjustments to reconcile net income to net cash from operations:
        		                                 
          gain on settlement of accounts payable
        		                                 
          share based compensation
        		7,828,000 3,504,000 2,055,000   2,286,000                            
          changes in working capital balances related to operations:
        		                                 
          incentive and tax receivables
        		1,629,000 1,783,000 -108,000 2,065,000 -236,000 -840,000                            
          prepaid expenses and deposits
        		483,000 229,000 220,000 286,000 -589,000 -103,000 402,156                           
          accounts payable
        		-2,887,000 -4,893,000 -5,060,000 -164,000 -566,000 -30,000                            
          accrued liabilities
        		-906,000 4,720,000 2,897,000 2,419,000 -2,371,000 -9,000                            
          deferred grant income
        		-37,000 -12,000 -13,000                               
          net cash from operating activities
        		-30,440,000 -17,976,000 -12,120,000 -5,180,000 -11,656,000 -7,318,000 -8,491,627                           
          capital expenditures
        		0 0 0 0 0 0 0                           
          free cash flows
        		-30,440,000 -17,976,000 -12,120,000 -5,180,000 -11,656,000 -7,318,000 -8,491,627                           
          cash flows from financing activities
        		                                 
          issuance of common shares
        		   4,106,000   5,068,834  500,000 500,000              1,675,000 1,183,075 433,126 2,362,447 -883,075 1,183,075 300,000 280,998 1,132,150  
          payment for taxes related to cashless exercise of options
        		-2,262,000                                 
          proceeds from exercise of stock options
        		1,679,000 1,560,000 708,000 444,000 99,000 59,000                            
          net cash from financing activities
        		-583,000 1,560,000 708,000 4,550,000 7,277,000 59,000 5,018,834  411,856 411,856 0 -53,872 9,445,160 188,170 827,937 33,348 50,000 200,000 245,100 78,250 283,750 962,500 -165,363 2,425,000 1,243,075 473,126 2,412,977 381,395 1,243,075 450,000 580,998 1,845,234 262,581 
          decrease in cash and cash equivalents during the period
        		-31,023,000 -16,416,000 -11,412,000   -7,259,000 -3,472,793                           
          cash and cash equivalents, beginning of period
        		132,187,000 132,187,000 132,187,000 0 0 151,024,000 22,930,638                           
          cash and cash equivalents, end of period
        		101,164,000 115,771,000 120,775,000 -630,000 -4,379,000 143,765,000 19,457,845                           
          supplemental cash flow information
        		                                 
          cash paid for state and local franchise taxes
        		109,000 36,000 43,000                               
          common stock issued upon cashless exercise of stock option
        		548,000 460,000                                
          anavex life sciences corp.
        		                                 
          condensed consolidated interim statements of changes in stockholders’ equity
        		                                 
          for the three months ended june 30, 2025 and 2024
        		                                 
          balance, april 1, 2025
        		85,333,652,000                                 
          shares issued pursuant to exercise of stock options
        		39,389,000  189,932,000                               
          shares issued pursuant to cashless exercise of stock option
        		50,000,000                                 
          shares withheld related to cashless exercise of stock option
        		-11,349,000                                 
          balance, june 30, 2025
        		85,411,692,000                                 
          balance, april 1, 2024
        		83,616,218,000                                 
          shares issued under 2023 purchase agreement
        		                                 
          purchase shares
        		950,000,000      1,279,592                           
          commitment shares
        		1,939,000      6,047                           
          balance, june 30, 2024
        		84,795,517,000                                 
          for the three months ended march 31, 2025 and 2024
        		                                 
          for the three months ended december 31, 2024 and 2023
        		                                 
          balance, october 1, 2024
        		  84,795,517,000                               
          balance, december 31, 2024
        		  84,985,449,000                               
          balance, october 1, 2023
        		  82,066,511,000                               
          balance, december 31, 2023
        		  82,086,511,000                               
          non-cash financing related charges
        		        29,000 29,000                        
          share-based compensation
        		   2,487,000                              
          increase in cash and cash equivalents during the period
        		   -630,000                              
          cash paid for state and local minimum income taxes
        		   0 173,000 47,000                            
          schedule of principal components of accrued liabilities
        		                                 
          accrued clinical site and patient visits costs
        		   -414,000                              
          accrued compensation and benefits
        		   400,000                              
          fixed contract accruals
        		                                 
          milestone based contract accruals
        		   1,686,000                              
          all other accrued liabilities
        		   747,000                              
          total accrued liabilities
        		   2,419,000                              
          schedule of accrued liabilities
        		                                 
          7
        		                                 
          stock based compensation
        		                        187,750  227,115 209,273 187,750 112,608   200,616 
          share issue costs
        		                                 
          9
        		                                 
          stock-based compensation
        		      3,960,139  31,544 15,362         0 98,800 80,144 123,264 257,747 159,186       256,546   
          changes in working capital balances:
        		                                 
          prepaid expenses and other current assets
        		                                 
          proceeds from exercise of warrants
        		                                 
          8
        		                                 
          see accompanying notes to condensed consolidated interim financial statements
        		                                 
          changes in non-cash working capital balances related to operations:
        		                                 
          clinical site costs and patient visits
        		                                 
          3
        		                                 
          balance, january 1, 2021
        		                                 
          shares issued under 2019 purchase agreement
        		                                 
          shares issued upon exercise of options
        		                                 
          shares issued under sales agreement, net of share issue costs
        		                                 
          balance, march 31, 2021
        		                                 
          balance, january 1, 2020
        		                                 
          balance, march 31, 2020
        		                                 
          5
        		                                 
          deferred costs
        		                                 
          deferred financing charges
        		      -50,000                           
          cash and cash equivalents, beginning of year
        		                                 
          cash and cash equivalents, end of year
        		                                 
          f-3
        		                                 
          balance, january 1, 2019
        		      46,887,056                           
          shares issued under 2015 purchase agreement
        		                                 
          shares issued pursuant to cashless exercise of warrants
        		      546                           
          balance, march 31, 2019
        		      48,173,241                           
          6
        		                                 
          sales tax recoverable
        		      -35,989                           
          deposits
        		      37,396                           
          accounts payable and accrued liabilities
        		      2,485,978  225,987 101,670     41,944 123,426 -19,723 320,264 423,297 349,032 1,507,736 987 17,737 289,698 111,205 293,086 56,747 50,806 111,205  642,166 -232,945 324,562 
          balance, april 1, 2019
        		                                 
          balance, june 30, 2019
        		                                 
          balance, april 1, 2018
        		                                 
          shares issued pursuant to cashless exercise of options
        		      970                           
          balance, june 30, 2018
        		                                 
          three months ended march 31, 2019 and 2018
        		                                 
          shares issued under purchase agreement
        		                                 
          balance, january 1, 2018
        		      44,421,992                           
          balance, march 31, 2018
        		      44,573,788                           
          issuance of common shares, net of share issue costs
        		          0 -30,000 210,000 188,170     0 0 283,750 712,500            
          balance, october 1, 2017
        		                                 
          balance, september 30, 2018
        		                                 
          balance, december 31, 2018
        		                                 
          amortization and depreciation
        		        498 249 192 192 192 192 0 0 111 465 464 465 465 464 382 377          
          accretion of debt discount
        		        493,451 7,120 1,916,524 80       0 15,293 44,613 38,175 40,019   595,319 921,871   220,410 150,833 11,550  
          gain on extinguishment of debt
        		                                 
          unrealized foreign exchange
        		                                 
          repayment of promissory notes
        		                                 
          increase in cash and cash equivalents during the year
        		                                 
          balance, october 1, 2015
        		                                 
          shares issued under purchase agreements
        		                                 
          capital stock issued pursuant to debt conversions - at 1.00
        		                                 
          shares issued pursuant to the exercise of warrants
        		                                 
          shares issued pursuant to employment agreement
        		                                 
          shares issued for rounding in connection with 4:1 reverse split
        		                                 
          stock option compensation
        		                                 
          balance, september 30, 2016
        		                                 
          balance, september 30, 2017
        		                                 
          balance, december 31, 2017
        		                                 
          change in fair value of derivative financial instruments
        		        487,000                         
          balance, october 1, 2014
        		                                 
          equity units issued under purchase agreement
        		                                 
          commitment shares issued under terms of purchase agreement
        		                                 
          capital stock issued for cash - at 1.00
        		                                 
          capital stock issued pursuant to subscriptions received - at 1.20
        		                                 
          shares issued pursuant to the exercise of warrants - at 1.20
        		                                 
          shares issued pursuant to the exercise of warrants - cashless
        		                                 
          shares issued pursuant to favored nations provision
        		                                 
          reclassification of derivative liability
        		                                 
          balance, september 30, 2015
        		                                 
          cash flows from financing activity
        		                                 
          net cash from financing activity
        		                                 
          increase in cash during the period
        		       7,329,645   -917,543 -1,013,877      68,427       159,114    159,114  -391,583 663,848  
          balance, october 1, 2016
        		                                 
          shares issued upon exercise of warrants - cashless
        		                                 
          net income for the period
        		                                 
          balance, june 30, 2017
        		                                 
          f-4
        		                                 
          shares subscribed
        		                                 
          cash, beginning of period
        		        7,262,138 7,262,138 0 0 0 345,074 0 0 0 11,362 0 0 0 134,702 0 0 264,669 0 0 86,325 264,669 350,994 0 0 6,357 
          cash, end of period
        		        6,310,643 6,980,924 -917,543 -1,013,877 9,097,631 95,927 343,429 1,158 -79,302 79,789 -6,833 -160,452 169,568 9,079 -1,087,952 1,219,013 423,783 -1,193,770 1,313,929 -279,273 423,783 21,034 -391,583 663,848 614 
          supplemental cash flow information - note 7
        		                                 
          cash flows from operating activities
        		                                 
          net loss
        		                                 
          adjustments to reconcile net loss to net cash from operations:
        		                                 
          amortization of deferred financing charge
        		          1,113,565 8,848   0 0 0 1,215 1,685 15,244 25,816 19,654            
          deferred income tax benefit
        		                                 
          loss on extinguishment of debt
        		                  5    0 0       0 0  
          cash flows from investing activities
        		                                 
          acquisition of equipment
        		                                 
          net cash from investing activities
        		                                 
          financing fees paid
        		                                 
          proceeds from the issuance of convertible debentures
        		          0                       
          repayment of promissory note
        		                                 
          decrease in cash during the period
        		                                 
          page 5
        		                                 
          (gain) on extinguishment of debt
        		                                 
          other
        		                                 
          gst recoverable
        		                                 
          prepaid expenses
        		                  0 0          3    
          net loss for the period
        		                                 
          deferred income tax expense
        		                                 
          cash flows used in investing activities
        		                                 
          exhibit number
        		                                 
          articles of incorporation and bylaws
        		                                 
          3.1
        		                                 
          3.2
        		                                 
          3.3
        		                                 
          3.4
        		                                 
          instruments defining rights of security holders, including indentures
        		                                 
          4.1
        		                                 
          4.2
        		                                 
          4.3
        		                                 
          4.4
        		                                 
          section 302 certifications
        		                                 
          31.1*
        		                                 
          section 906 certifications
        		                                 
          32.1*
        		                                 
          xbrl
        		                                 
          101.ins*
        		                                 
          101.sch*
        		                                 
          101.cal*
        		                                 
          101.def*
        		                                 
          101.lab*
        		                                 
          101.pre*
        		                                 
          common shares to be issued for services
        		           0                      
          share subscriptions received
        		              26,652          60,000   89,470 60,000    128,081 
          supplemental cash flow information - note 11
        		                                 
          stock–based compensation
        		                                 
          loss on settlement of accounts payable
        		                      84,963 0          
          changes in non–cash working capital balances related to operations:
        		                                 
          proceeds from the issuance of promissory notes
        		                                 
          supplemental cash flow information – note 11
        		                                 
          consulting expense recorded in exchange for shares to be issued
        		                                 
          common shares issued for consulting expenses
        		                  -1 1           -236,337  134,450 
          promissory note issued for severance
        		                                 
          common shares issued for severance
        		                                 
          common shares issued for research and development expenses
        		                                 
          management fees contributed
        		                                 
          debt conversion expense
        		                      0 0 504,160    504,160     
          rent contributed
        		                                 
          vat recoverable
        		                  0    20,549           
          proceeds from promissory notes
        		              0 0 50,000 200,000 250,000 81,500 0 250,000 0   40,000 200,000   150,000   134,500 
          financing fees
        		                                 
          issuance of convertible debentures
        		                                 
          due to related parties
        		                                 
          shareholder advances
        		                                 
          capital stock issued for cash on january 23, 2004 - at 0.0033
        		                                 
          net income from january 23, 2004 to september 30, 2004
        		                                 
          balance, september 30, 2004
        		                                 
          capital stock issued for cash on december 31, 2004 - at 0.0033
        		                                 
          net income for the year
        		                                 
          balance, september 30, 2005
        		                                 
          debt forgiven by directors
        		                                 
          balance, september 30, 2006
        		                                 
          capital stock issued for research and development services on september 24, 2007 - at 3.60
        		                                 
          capital stock issued for settlement of loan payable on september 25, 2007 - at 3.60
        		                                 
          balance, september 30, 2007
        		                                 
          net gain (lossl for the period
        		             358,637                    
          change in fair value of derivative liability
        		                         -362,458        
          supplemental cash flow information - note 10
        		                                 
          adjustments to reconcile net loss to net cash used in operations:
        		                                 
          deferred financing fee
        		                                 
          supplemental cash flow information - note 8
        		                                 
          common shares to be issued for severance
        		                                 
          extension of warrants for research and development expenses
        		                                 
          supplemental cash flow information - note 9
        		                                 
          financing fee
        		                                 
          vat receivable
        		                        37,820    37,820     
          amortization
        		                        491  190 -111 491 190  80 90 
          amortization of deferred financing costs
        		                          12,793   5,826    
          consulting expense recorded in exchange for shares to be issued – note 8
        		                                 
          promissory note issued for severance – notes 6 and 7
        		                                 
          adjustments to reconcile net loss to net cash used
        		                                 
          in operating activities:
        		                                 
          consulting expense recorded in exchange for
        		                                 
          shares to be issued
        		                                 
          common shares issued for consulting expense
        		                                 
          common shares issued for research and
        		                                 
          development expenses
        		                                 
          interest accrued on promissory notes
        		                                 
          changes in assets and liabilities:
        		                                 
          loan payable to shareholder
        		                                 
          add items not involving cash:
        		                                 
          adjustments to reconcile net loss to net cash from operating activities:
        		                                 
          interim consolidated statement of changes in capital deficit
        		                                 
          for the period january 23, 2004 (date of inception) to december 31, 2010
        		                                 
          consulting expense recorded in exchange for shares
        		                                 
          to be issued
        		                                 
          common shares issued for research and development
        		                                 
          expenses
        		                                 
          adjustments to reconcile net loss to net cash from
        		                                 
          operating activities:
        		                                 
          acquisition of capital assets
        		                                 
          supplemental cash flow information – note 9
        		                                 
          operations:
        		                                 
          consulting expense recorded in exchange for shares to be
        		                                 
          issued – note 4
        		                                 
          promissory note issued for severance – notes 5 and 6
        		                                 
          changes in non-cash working capital balances related to
        		                                 
          promissory note proceeds
        		                                 
          promissory note repayments
        		                                 
          non cash transactions – note 7
        		                                 
          stock-based compensation – note 7
        		                                 
          common shares to be issued for consulting services
        		                                 
          adjustments to reconcile net income to net cash used
        		                                 
          statement of changes in capital deficit
        		                                 
          for the period january 23, 2004 (date of inception) to june 30, 2009
        		                                 
          supplemental cash flow information – note 7
        		                                 
          adjustments to reconcile net income to net cash from
        		                                 
          common stock
        		                                 
          shares
        		                                 
          capital stock issued for research and development services on
        		                                 
          september 24, 2007 - at 3.60
        		                                 
          capital stock issued for settlement of loan payable on
        		                                 
          september 25, 2007 - at 3.60
        		                                 
          balance, september 30, 2007 – carried forward